×







We sell 100% Genuine & New Books only!

Cardiovascular Safety in Drug Development and Therapeutic Use New Methodologies and Evolving Regulatory Landscapes 1st Editon 2016 Hardbound at Meripustak

Cardiovascular Safety in Drug Development and Therapeutic Use New Methodologies and Evolving Regulatory Landscapes 1st Editon 2016 Hardbound by J. Rick Turner, Dilip R. Karnad, Snehal Kothari, Springer

Books from same Author: J. Rick Turner, Dilip R. Karnad, Snehal Kothari

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Price: ₹ 11133.00/- [ 15.00% off ]

    Seller Price: ₹ 9463.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)J. Rick Turner, Dilip R. Karnad, Snehal Kothari
    PublisherSpringer
    Edition1st Editon
    ISBN9783319403458
    Pages342
    BindingHardbound
    LanguageEnglish
    Publish YearJuly 2016

    Description

    Springer Cardiovascular Safety in Drug Development and Therapeutic Use New Methodologies and Evolving Regulatory Landscapes 1st Editon 2016 Hardbound by J. Rick Turner, Dilip R. Karnad, Snehal Kothari

    At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.“a resource that will likely serve as a standard for years to come” - Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180“I have no hesitation in recommending this book as a valuable reference source” - Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63 The Central Importance of Cardiovascular Safety in Contemporary New Drug Development.- The Biological Basis of Drug Responses.- Cardiovascular Structure, Function, Pathophysiology, & Disease.- The Current Regulatory Landscape.- The 'Comprehensive In Vitro Proarrhythmia Assay' Initiative.- The 'Early ECG Assessment' Initiative.- The 'Submission of Extended Digital ECG Data' Initiative.- Meta-analysis and Meta-methodology.- Current Regulatory Landscapes and their Potential Evolution.- Off-target Blood Pressure Responses to Non-cardiovascular Drugs.- Oncology Drug Development and Therapeutics: Cardiotoxicity Considerations.- Postmarketing Surveillance.- Regulatory Perspectives on General Drug Safety.- Future Directions in Cardiovascular Safety.- References.



    Book Successfully Added To Your Cart